- Home
- EMBC vs ATXS Comparison
EMBC vs ATXS Comparison
Compare EMBC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- ATXS
- Stock Information
- Founded
- EMBC 1924
- ATXS 2008
- Country
- EMBC United States
- ATXS United States
- Employees
- EMBC N/A
- ATXS N/A
- Industry
- EMBC Medical/Dental Instruments
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- EMBC Health Care
- ATXS Health Care
- Exchange
- EMBC Nasdaq
- ATXS Nasdaq
- Market Cap
- EMBC 753.0M
- ATXS 669.8M
- IPO Year
- EMBC N/A
- ATXS 2015
- Fundamental
- Price
- EMBC $14.62
- ATXS $9.37
- Analyst Decision
- EMBC Sell
- ATXS Strong Buy
- Analyst Count
- EMBC 1
- ATXS 5
- Target Price
- EMBC $12.00
- ATXS $25.60
- AVG Volume (30 Days)
- EMBC 247.0K
- ATXS 219.2K
- Earning Date
- EMBC 11-26-2024
- ATXS 11-13-2024
- Dividend Yield
- EMBC 4.10%
- ATXS N/A
- EPS Growth
- EMBC 45.34
- ATXS N/A
- EPS
- EMBC 1.20
- ATXS N/A
- Revenue
- EMBC $1,118,900,000.00
- ATXS N/A
- Revenue This Year
- EMBC $1.45
- ATXS N/A
- Revenue Next Year
- EMBC $0.53
- ATXS N/A
- P/E Ratio
- EMBC $12.17
- ATXS N/A
- Revenue Growth
- EMBC 0.48
- ATXS N/A
- 52 Week Low
- EMBC $9.93
- ATXS $4.26
- 52 Week High
- EMBC $19.79
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- EMBC 48.99
- ATXS 30.44
- Support Level
- EMBC $14.81
- ATXS $11.40
- Resistance Level
- EMBC $16.19
- ATXS $11.75
- Average True Range (ATR)
- EMBC 0.68
- ATXS 0.75
- MACD
- EMBC 0.02
- ATXS -0.23
- Stochastic Oscillator
- EMBC 27.69
- ATXS 7.64
About EMBC Embecta Corp.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.